Alexion Pharmaceuticals (Alexion Pharmaceuticals) EBIT : $614 Mil (TTM As of Mar. 2021)

View and export this data going back to 1996. Start your Free Trial

What is Alexion Pharmaceuticals EBIT?

Alexion Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2021 was $630 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2021 was $614 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Alexion Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2021 was 19.10%. Alexion Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2021 was 84.31%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Alexion Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2021 was 1.55%.

Alexion Pharmaceuticals EBIT Historical Data

The historical data trend for Alexion Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexion Pharmaceuticals EBIT Chart

Alexion Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

EBIT

Get a 7-Day Free Trial

673.10

646.20

340.40

2,256.60

673.70

Alexion Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
EBIT	Get a 7-Day Free Trial															689.40	-1,328.50	694.50	618.30	629.70

Competitive Comparison of Alexion Pharmaceuticals's EBIT

For the Biotechnology subindustry, Alexion Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alexion Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alexion Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alexion Pharmaceuticals's EV-to-EBIT falls into.

Alexion Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $614 Mil.

Alexion Pharmaceuticals (NAS:ALXN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Alexion Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2021 is calculated as:

	ROC % (Q: Mar. 2021 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2020 )	+	Invested Capital (Q: Mar. 2021 ))	/ count )
=	3303.6 * ( 1 - 18.82% )	/	( (13932	+	14144.9)	/ 2 )
=	2681.86248	/	14038.45
=	19.10 %

where

	Invested Capital		(Q: Dec. 2020 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	18103	-	1171.6	-	( 2999.4	-	max(0, 1624.7	-	5833	+	2999.4	))
=	13932

	Invested Capital		(Q: Mar. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	18650.2	-	1036	-	( 3469.3	-	max(0, 1426.2	-	6452.6	+	3469.3	))
=	14144.9

Note: The Operating Income data used here is four times the quarterly (Mar. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

Alexion Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2021 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2021 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2020		Q: Mar. 2021
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	2518.8	/	( ( (1461.9 + max(1351.3, 0))	+	(1461.6 + max(1700.3, 0)) )	/	2 )
=	2518.8	/	( ( 2813.2	+	3161.9 )	/	2 )
=	2518.8	/	2987.55
=	84.31 %

where Working Capital is:

	Working Capital		(Q: Dec. 2020 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1409.3	+	775.7	+	648.6)	-	(1171.6	+	0	+	310.7)
=	1351.3

	Working Capital		(Q: Mar. 2021 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1473	+	803.9	+	706.4)	-	(1036	+	0	+	247)
=	1700.3

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2021) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Alexion Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2021 )
	=	614	/	39583.709
	=	1.55 %

Alexion Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Alexion Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alexion Pharmaceuticals Inc (NAS:ALXN) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Seaport Boulevard, Boston, MA, USA, 02210

Website

https://www.alexion.com

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Executives

Daniel Bazarko	officer: SVP, Controller, CAO	C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210
Tanisha Carino	officer: EVP & CCAO	C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Anne-marie Law	officer: EVP, Chief Experience Officer	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Brian Goff	officer: EVP & Chief Commercial Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John J Orloff	officer: EVP, Research & Development	C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Indrani Lall Franchini	officer: EVP, Chief Compliance Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John T Mollen	director	176 SOUTH STREET HOPKINTON MA 01748
David R Brennan	director	C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Baker Bros. Advisors (gp) Llc	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Andreas Rummelt	director	C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Baker Brothers Life Sciences Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Deborah Dunsire	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Judith A Reinsdorf	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974